Fig 2: Subgroup divided by SLC11A1 predict potential immunotherapy responses of gliomas and identification of candidate agents with higher drug sensitivity in glioma patients. (E) Comparison of estimated olaparib (up) and temozolomide’s (down) sensitivity (logAUC) between IDH mutant and wildtype groups. (F) Comparison of estimated temozolomide’s sensitivity (logAUC) between high-SLC11A1 and low-SLC11A1 groups. (G) Spearman’s correlation analysis of three CTRP-derived compounds (up) and ten PRISM-derived compounds (down).

Fig 3: Expression of SLC11A1 increased with the progression of glioma. (A) Univariate and multivariate analysis for overall survival of glioma patients. (B) CGGA, (C) TCGA, (D) Rembrandt, (E) GSE16011, (F) GSE4412, and (G) GSE43289. (The X-axis represents the WHO grade while the Y-axis represents SLC11A1 expression value (log2). Based on Wilcoxon test.) (H) qRT-PCR of SLC11A1 of 20 patients with gliomas. (I) Representations and quantification of immunohistochemistry detection of SLC11A1 in LGG (low grade glioma) and HGG (high grade glioma). *,P < 0.05; **,P < 0.01; ***,P < 0.001, ns = no significance (Wilcoxon test). (J) Western blot of SLC11A1 in LGG (low grade glioma) and HGG (high grade glioma).

Fig 4: SLC11A1 is associated with immune infiltration and immune activation in gliomas. (A) STRING database shows the PPI network of SLC11A1. (B) GO (Gene Ontology) results for differential expression genes (Cut-off criteria for DEGs significance was adj. p value< 0.05 and the absolute value of the log2FC= 1.5). The X-axis represents gene ratio and the Y-axis represents different enriched pathways (BP: biological progress; CC: cellular component; MF: molecular function). (C) Rank-based gene set enrichment analysis shows significantly activated hallmark pathways in SLC11A1 high subgroup compared with low subgroup. (D) Heatmap showing SLC11A1-associated relative abundance of 28 immune cells in gliomas (CGGA), annotations show corresponding clinical features of each sample. (E) Heatmap showing SLC11A1-associated relative abundance of 28 immune cells in gliomas (TCGA), annotations show corresponding clinical features of each sample.

Fig 5: Pan-cancer analysis of SLC11A1 expression. (A) UCSCXenaShiny was used to visualize SLC11A1 expression in the cancer genome atlas (TCGA) pan-cancer datasets. (B) Risk plot of correlation SLC11A1 with OS, PFI, DSS (red represents HR > 1(risky) and P value < 0.05; blue represents HR < 1 (protective) and P value < 0.05; grey represents no statistical significance). **,P < 0.01; ***,P < 0.001; ****,P < 0.0001, ns = no significance (Wilcoxon test).